VIR

Vir Biotechnology, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE · CIK 0001706431
$8.61 +1.06% $1.5B
Insider Selling Cluster (2 insiders)17 New Institutional Positions4 Institutional Exits
Vol
Market Cap$1.5B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders50 funds
Inst. Value$622.2M
Inst. Activity17 buys / 4 sells
Insider Activity0B / 20S
Insider Net $-$2.2M
SEC Reports14
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001706431·Prev Close $8.52

Recent Activity

Jun 10, 2026 SEC
Timothy Coughlin filed a Form 3 initial statement of beneficial ownership with the SEC, reporting zero shares of Vir Bio
3 — Impact 1/10
Jun 10, 2026 SEC
Vir Biotechnology appointed Timothy Coughlin, CPA, as a new Class III director and Audit Committee Chair, expanding the
8-K — Impact 2/10
Jun 9, 2026 Insider
Coughlin Timothy was granted 8,000 shares
Director
Jun 9, 2026 Insider
Coughlin Timothy was granted 16,000 shares
Director
Jun 3, 2026 short_volume
Short Volume: VIR — 65.0% short (0.7M / 1.1M)
Short: 687,834 | Exempt: 94 | TRF Vol: 1,058,683 | Short Ratio: 65.0% | Off-exchange volume (dark po
Jun 2, 2026 SEC
Two insiders at Vir Biotechnology sold a combined $34K in open-market sales on June 1, 2026, following a wave of non-cas
CLUSTER — Impact 2/10
Jun 1, 2026 Insider
Sabatini Brent sold 379 shares
SVP, Chief Accounting Officer @ $9.45 ($3.6K)
Inst.
FMR LLC — TRIM
2,071,848 shares ($18.6M)

Price Targets

$21.56 +150.4% upside Strong Buy
Current $8.61 Low $16.00 Median $21.00 High $30.00 9 analysts
$16.00 $30.00

Analyst Ratings

Strong Buy93% buy · 14 analysts
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 11, 2026 Morgan Stanley MAINTAIN Overweight → Overweight
Jun 3, 2026 Leerink Partners MAINTAIN Outperform → Outperform
Mar 4, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Feb 25, 2026 Barclays MAINTAIN Overweight → Overweight
Feb 24, 2026 Morgan Stanley MAINTAIN Overweight → Overweight

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.90 $0.47 — $1.45 212% YoY 5
Next Q $-0.81 ▼ -1.5% $-1.02 — $-0.65 31% YoY 5
Current FY $-1.37 ▼ -1.6% $-1.74 — $-1.20 57% YoY 5
Next FY $-2.32 ▼ -1.1% $-2.99 — $-1.87 -69% YoY 4

Latest Reports

NEUTRAL 3 1/10
Timothy Coughlin filed a Form 3 initial statement of beneficial ownership with the SEC, reporting zero shares of Vir Bio
Jun 10, 2026
NEUTRAL 8-K 2/10
Vir Biotechnology appointed Timothy Coughlin, CPA, as a new Class III director and Audit Committee Chair, expanding the
Jun 10, 2026

Top Institutional Holders

FundValueMove
NOMURA ASSET MANAGEMENT CO——
BlackRock, Inc.$161.3M—
VANGUARD PORTFOLIO MANAGEMENT LLC$82.6M—
STATE STREET CORP$64.0M—
VANGUARD CAPITAL MANAGEMENT LLC$48.2M—

Recent Insider Trades

DateInsiderTypeValue
Jun 9, 2026Coughlin TimothyA$0.00
Jun 9, 2026Coughlin TimothyA$0.00
Jun 1, 2026Sabatini BrentSELL$3.6K
Jun 1, 2026Napolitano JanetSELL$30.2K
May 27, 2026Napolitano JanetA$0.00
50 institutional holders with $622.2M total value (69,501,690 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, VANGUARD. Net buying activity: 17 institutions added/increased vs 4 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1NOMURA ASSET MANAGEMENT CO LTD—$0.000.0%—
2BlackRock, Inc.17,998,329$161.3M25.9%—
3VANGUARD PORTFOLIO MANAGEMENT LLC9,215,577$82.6M13.3%—
4STATE STREET CORP7,141,094$64.0M10.3%—
5VANGUARD CAPITAL MANAGEMENT LLC5,382,103$48.2M7.8%—
6GOLDMAN SACHS GROUP INC3,250,227$29.1M4.7%—
7MORGAN STANLEY2,854,205$25.6M4.1%ADD +64.6%
8DIMENSIONAL FUND ADVISORS LP2,579,678$23.1M3.7%—
9CITADEL ADVISORS LLC2,098,476$18.8M3.0%NEAR_EXIT -76.9%
10FMR LLC2,071,848$18.6M3.0%TRIM -34.4%
11Point72 Asset Management, L.P.1,952,234$17.5M2.8%DOUBLED +897.5%
12Pictet Asset Management Holding SA1,480,828$13.3M2.1%DOUBLED +10878.9%
13Hudson Bay Capital Management LP1,469,510$13.2M2.1%ADD +45.3%
14TWO SIGMA INVESTMENTS, LP1,439,494$12.9M2.1%ADD +75.7%
15CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,171,684$10.5M1.7%ADD +29.5%
16Nuveen, LLC1,018,964$9.1M1.5%ADD +80.2%
17BANK OF AMERICA CORP /DE/965,814$8.7M1.4%DOUBLED +132.2%
18D. E. Shaw & Co., Inc.817,685$7.3M1.2%ADD +48.5%
19RENAISSANCE TECHNOLOGIES LLC761,364$6.8M1.1%TRIM -47.4%
20VANGUARD FIDUCIARY TRUST CO731,721$6.6M1.1%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
FMR LLCTRIM3,158,4162,071,848-34.4%$18.6M2026-Q1
Point72 Asset Management, L.P.DOUBLED195,7181,952,234+897.5%$17.5M2026-Q1
Pictet Asset Management Holding SADOUBLED13,4881,480,828+10878.9%$13.3M2026-Q1
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD904,4801,171,684+29.5%$10.5M2026-Q1
Nuveen, LLCADD565,5441,018,964+80.2%$9.1M2026-Q1
AMERIPRISE FINANCIAL INCTRIM731,307395,038-46.0%$3.5M2026-Q1
Erste Asset Management GmbHDOUBLED28,800180,800+527.8%$1.5M2026-Q1
PRUDENTIAL FINANCIAL INCTRIM281,542115,402-59.0%$1.0M2026-Q1
DEUTSCHE BANK AG\TRIM206,22290,733-56.0%$813.0K2026-Q1
Russell Investments Group, Ltd.DOUBLED7,50082,213+996.2%$736.6K2026-Q1
JANUS HENDERSON GROUP PLCADD37,05754,789+47.9%$490.6K2026-Q1
MetLife Investment Management, LLCADD37,72250,546+34.0%$452.9K2026-Q1
Rockefeller Capital Management L.P.ADD29,86939,323+31.7%$352.3K2026-Q1
CWM, LLCDOUBLED8,80437,645+327.6%$337.3K2026-Q1
CAPTRUST FINANCIAL ADVISORSADD19,77437,555+89.9%$336.5K2026-Q1
Cerity Partners LLCDOUBLED16,08935,864+122.9%$321.3K2026-Q1
SEI INVESTMENTS COADD26,32635,202+33.7%$315.4K2026-Q1
FIFTH THIRD BANCORPDOUBLED1,85326,324+1320.6%$235.9K2026-Q1
WEALTH ENHANCEMENT ADVISORY SERVICES, LLCDOUBLED10,74725,319+135.6%$229.4K2026-Q1
AmundiADD10,02115,315+52.8%$137.2K2026-Q1
NISA INVESTMENT ADVISORS, LLCDOUBLED2,0955,562+165.5%$49.8K2026-Q1
Hudson Bay Capital Management LPADD911,8821,325,000+45.3%$8.0M2025-Q4
BANK OF AMERICA CORP /DE/DOUBLED400,983930,908+132.2%$5.6M2025-Q4
AMERIPRISE FINANCIAL INCDOUBLED194,269731,307+276.4%$4.4M2025-Q4
RENAISSANCE TECHNOLOGIES LLCTRIM1,167,100614,464-47.4%$3.7M2025-Q4
13 unique insiders with 47 transactions. Net insider value: -$2.2M ($0.00 bought, $2.2M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 9, 2026Coughlin TimothyDirectorAWARD8,000——
Jun 9, 2026Coughlin TimothyDirectorAWARD16,000——
Jun 1, 2026Sabatini BrentSVP, Chief Accounting OfficerSELL379$9.45$3.6K
Jun 1, 2026Napolitano JanetDirectorSELL3,200$9.45$30.2K
May 27, 2026Napolitano JanetDirectorAWARD8,000——
May 27, 2026BISCHOFBERGER NORBERT WDirectorAWARD8,000——
May 27, 2026BISCHOFBERGER NORBERT WDirectorAWARD16,000——
May 27, 2026Farid RamyDirectorAWARD8,000——
May 27, 2026Farid RamyDirectorAWARD16,000——
May 27, 2026Hatfield Jeffrey S.DirectorAWARD8,000——
May 27, 2026Hatfield Jeffrey S.DirectorAWARD16,000——
May 27, 2026MORE ROBERT JDirectorAWARD8,000——
May 27, 2026MORE ROBERT JDirectorAWARD16,000——
May 27, 2026Napolitano JanetDirectorAWARD16,000——
May 27, 2026Sigal Charles ElliottDirectorAWARD8,000——
May 27, 2026Sigal Charles ElliottDirectorAWARD16,000——
May 1, 2026SATO VICKI LDirectorSELL22,000$10.05$221.0K
Apr 29, 2026De Backer MariannePresident and CEOJ233,532——
Apr 6, 2026De Backer MariannePresident and CEOSELL72,559$9.16$664.4K
Apr 1, 2026SATO VICKI LDirectorSELL22,000$9.07$199.6K
Mar 23, 2026Sabatini BrentSVP, Chief Accounting OfficerSELL7,711$9.12$70.3K
Mar 20, 2026O'Byrne JasonEVP & Chief Financial OfficerJ2,500——
Mar 2, 2026SATO VICKI LDirectorSELL21,800$9.50$207.2K
Feb 25, 2026Eisner MarkEVP and Chief Medical OfficerSELL1,889$9.82$18.5K
Feb 25, 2026de Verneuil VaninaEVP, General Counsel, Corp SecSELL13,700$9.82$134.5K
Feb 24, 2026Sabatini BrentSVP, Chief Accounting OfficerSELL1,430$9.53$13.6K
Feb 24, 2026de Verneuil VaninaEVP, General Counsel, Corp SecSELL3,117$9.53$29.7K
Feb 24, 2026O'Byrne JasonEVP & Chief Financial OfficerSELL1,634$9.53$15.6K
Feb 24, 2026SATO VICKI LDirectorEXERCISE42,377$1.49$62.9K
Feb 24, 2026Eisner MarkEVP and Chief Medical OfficerSELL1,616$9.53$15.4K
Feb 24, 2026De Backer MarianneChief Executive OfficerSELL14,762$9.53$140.7K
Feb 23, 2026de Verneuil VaninaEVP, General Counsel, Corp SecSELL4,445$7.45$33.1K
Feb 23, 2026De Backer MarianneChief Executive OfficerSELL19,039$7.45$141.9K
Feb 23, 2026Sabatini BrentSVP, Chief Accounting OfficerSELL1,829$7.45$13.6K
Feb 23, 2026O'Byrne JasonEVP & Chief Financial OfficerSELL2,089$7.45$15.6K
Feb 23, 2026Eisner MarkEVP and Chief Medical OfficerSELL2,089$7.45$15.6K
Feb 22, 2026Sabatini BrentSVP, Chief Accounting OfficerAWARD25,000——
Feb 22, 2026Sabatini BrentSVP, Chief Accounting OfficerAWARD50,000——
Feb 22, 2026O'Byrne JasonEVP & Chief Financial OfficerAWARD55,000——
Feb 22, 2026Eisner MarkEVP and Chief Medical OfficerAWARD110,000——
Feb 22, 2026de Verneuil VaninaEVP, General Counsel, Corp SecAWARD55,000——
Feb 22, 2026de Verneuil VaninaEVP, General Counsel, Corp SecAWARD110,000——
Feb 22, 2026Eisner MarkEVP and Chief Medical OfficerAWARD55,000——
Feb 22, 2026O'Byrne JasonEVP & Chief Financial OfficerAWARD110,000——
Feb 22, 2026De Backer MarianneChief Executive OfficerAWARD285,000——
Feb 22, 2026De Backer MarianneChief Executive OfficerAWARD570,000——
Feb 2, 2026SATO VICKI LDirectorSELL22,000$7.71$169.7K
14 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 10 neutral. Avg impact: 3.6/10.
NEUTRAL 3 1/10
Timothy Coughlin filed a Form 3 initial statement of beneficial ownership with the SEC, reporting ze
Jun 10, 2026
NEUTRAL 8-K 2/10
Vir Biotechnology appointed Timothy Coughlin, CPA, as a new Class III director and Audit Committee C
Jun 10, 2026
NEUTRAL CLUSTER 2/10
Two insiders at Vir Biotechnology sold a combined $34K in open-market sales on June 1, 2026, followi
Jun 2, 2026
NEUTRAL 8-K 2/10
Vir Biotechnology filed an 8-K reporting the departure of board member and Audit Committee Chair Sai
May 28, 2026
NEUTRAL DEFA14A 3/10
Vir Biotechnology filed a definitive proxy statement (DEFA14A) following the recent departure of its
Apr 16, 2026
NEUTRAL 8-K 3/10
Vir Biotechnology's Chief Medical Officer, Mark Eisner, is stepping down effective April 24, 2026, a
Apr 10, 2026
BEARISH CLUSTER 6/10
Vir Biotechnology's CEO and a board director collectively sold $864K worth of shares in the past wee
Apr 7, 2026
NEUTRAL 8-K 3/10
Vir Biotechnology appointed CEO Marianne De Backer to the additional role of President. This is an i
Mar 4, 2026
BEARISH CLUSTER 5/10
Three corporate insiders at Vir Biotechnology sold shares in the past seven days, including two exec
Mar 3, 2026
BEARISH CLUSTER 5/10
Multiple C-suite executives at Vir Biotechnology, including the CEO, CFO, and General Counsel, condu
Feb 26, 2026
NEUTRAL CLUSTER 4/10
Multiple top executives at Vir Biotechnology, including the CEO, CFO, and CMO, sold shares worth ove
Feb 25, 2026
NEUTRAL CLUSTER 4/10
Multiple top executives at Vir Biotechnology, including the CEO, CFO, and Chief Medical Officer, sol
Feb 25, 2026
BEARISH CLUSTER 6/10
Multiple C-suite executives at Vir Biotechnology, including the CEO, CMO, and General Counsel, sold
Feb 25, 2026
NEUTRAL CLUSTER 4/10
CEO Marianne De Backer and EVP Vanina de Verneuil sold significant shares in Vir Biotechnology, tota
Feb 25, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$21.56 mean target +150.4% upside Strong Buy (1.30)
$16.00 Low $30.00 High
MetricValue
Current Price$8.61
Target Low$16.00
Target Mean$21.56
Target Median$21.00
Target High$30.00
# Analysts9
RecommendationStrong Buy (1.30)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.90 $0.47 $1.45 211.9% +0.0% — $0.2B 18233.6% 5
Next Q
2026-09-30
 $-0.81 $-1.02 $-0.65 31.1% -1.5% 2↑ 0↓ $0.0B 33.3% 5
Current FY
2026-12-31
 $-1.37 $-1.74 $-1.20 56.5% -1.6% 2↑ 2↓ $0.2B 263.8% 5
Next FY
2027-12-31
 $-2.32 $-2.99 $-1.87 -69.2% -1.1% 2↑ 2↓ $0.1B -54.7% 4

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.895
7d ago$0.895
30d ago$0.895
60d ago$-0.633+1.529
90d ago$-0.633+1.529
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 11, 2026 Morgan Stanley MAINTAIN Overweight Overweight
Jun 3, 2026 Leerink Partners MAINTAIN Outperform Outperform
Mar 4, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Feb 25, 2026 Barclays MAINTAIN Overweight Overweight
Feb 24, 2026 Morgan Stanley MAINTAIN Overweight Overweight
Feb 24, 2026 Evercore ISI Group MAINTAIN Outperform Outperform
Feb 24, 2026 Needham MAINTAIN Buy Buy
Feb 9, 2026 Needham REITERATE Buy Buy
Dec 30, 2025 HC Wainwright & Co. REITERATE Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264910093%
May 1, 20264910093%
Apr 1, 20264910093%
Mar 1, 202631010093%
Feb 1, 202631010093%
Jan 1, 202631010093%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 3, 2026
short_volume
Short Volume: VIR — 65.0% short (0.7M / 1.1M)
Short: 687,834 | Exempt: 94 | TRF Vol: 1,058,683 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: VIR — 56.7% short (0.6M / 1.1M)
Short: 603,778 | Exempt: 900 | TRF Vol: 1,065,769 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: VIR — 66.7% short (0.6M / 0.9M)
Short: 611,780 | Exempt: 3,300 | TRF Vol: 917,722 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
May 23, 2026
Clinical Trial
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Phase Phase 2 — COMPLETED
May 23, 2026
clinical_trial_readout
Results Pending: VIR-2218 (Phase 2) — Completed 68d ago
Trial: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection Sponsor: Vir Biotechnology, Inc. Phase: Phase
May 19, 2026
short_volume
Short Volume: VIR — 68.6% short (0.4M / 0.6M)
Short: 413,944 | Exempt: 128 | TRF Vol: 603,146 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: VIR — 61.3% short (0.3M / 0.5M)
Short: 320,030 | Exempt: 3,921 | TRF Vol: 522,021 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: VIR — 56.6% short (0.3M / 0.6M)
Short: 318,111 | Exempt: 2,654 | TRF Vol: 561,827 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
VIR Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
earnings_calendar
VIR Q1 2026 Earnings Scheduled — 2026-04-30
Apr 23, 2026
clinical_trial_readout
Results Pending: VIR-2218 (Phase 2) — Completed 38d ago
Trial: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection Sponsor: Vir Biotechnology, Inc. Phase: Phase
Apr 16, 2026
Clinical Trial
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Phase Phase 2 — COMPLETED
Apr 15, 2026
short_volume
Short Volume: VIR — 64.7% short (0.7M / 1.1M)
Short: 706,046 | Exempt: 0 | TRF Vol: 1,091,030 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: VIR — 59.2% short (0.6M / 1.0M)
Short: 612,607 | Exempt: 20,031 | TRF Vol: 1,035,610 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: VIR — 63.1% short (0.4M / 0.6M)
Short: 394,202 | Exempt: 30 | TRF Vol: 624,702 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
short_volume
Short Volume: VIR — 56.5% short (0.5M / 0.8M)
Short: 472,024 | Exempt: 7,304 | TRF Vol: 835,922 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: VIR — 59.7% short (0.6M / 0.9M)
Short: 551,516 | Exempt: 710 | TRF Vol: 924,170 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)